EUVIMEDEUVIMED entdecken
Open Access

Evaluation of time-to-onset and outcome of cardiac adverse events related to pembrolizumab using post-marketing surveillance in Japanese patients

Yuko Kanbayashi, Eren Tsuchiya, Tadashi Shimizu, Mayako Uchida

DARU Journal of Pharmaceutical Sciences · 2024

DOI: 10.1007/s40199-024-00516-z ↗

Kurz gefasst

Fachartikel in der Zeitschrift DARU Journal of Pharmaceutical Sciences, 2024. Verfasst von Yuko Kanbayashi und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Education and Research Center for Clinical Pharmacy, Faculty of Pharmacy, Osaka Medical and Pharmaceutical University, 4-20-1 Nasahara,…. Hauptthemen laut MEDLINE: Antibodies, Monoclonal, Humanized, Product Surveillance, Postmarketing, Antineoplastic Agents, Immunological. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 37 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: Pembrolizumab has been widely used in patients since its release, but information on cardiac Adverse Events (AEs) related to pembrolizumab remains lacking, particularly in Japanese populations. OBJECTIVES: This study aims to evaluate time to onset, incidence rates, and outcomes for pembrolizumab-induced cardiac AEs in patients with cancer using the Japanese Adverse Drug Event Report database. METHODS: We analysed data for the period from April 2004 to March 2022. Data on cardiac AEs were extracted and relative risks of AEs were estimated using the reporting odds ratio. RESULTS: We analysed 2,021,907 reports and identified 15,306 reports of AEs caused by pembrolizumab. Of these, 399 cardiac AEs were associated with pembrolizumab. Signals were detected for six cardiac AEs: myocarditis, immune-mediated myocarditis, pericardial effusion, cardiac tamponade, pericarditis, and pericarditis malignant. A histogram of median times to onset showed occurrence from 33 (21-97) days for immune-mediated myocarditis to 138 (67-168) days for pericarditis malignant, but some cases occurred even more than 1 year after the start of administration. Among these, myocarditis was the most frequently reported (27.1%), with fatal cases also reported. CONCLUSION: This study focused on cardiac AEs caused by pembrolizumab as post-marketing AEs. Patients should be monitored not only at the time of administration, but also over time for signs of these AEs, especially myocarditis, as some patients may have serious outcomes.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antibodies, Monoclonal, HumanizedProduct Surveillance, PostmarketingAntineoplastic Agents, ImmunologicalHumansJapanMaleFemaleMiddle AgedAgedAdultAdverse Drug Reaction Reporting SystemsNeoplasmsIncidenceTime FactorsDatabases, FactualCardiotoxicityMyocarditisAged, 80 and overEast Asian People

Substanzen

Antibodies, Monoclonal, HumanizedpembrolizumabAntineoplastic Agents, Immunological

Autor:innen und Institutionen

  • Department of Education and Research Center for Clinical Pharmacy, Faculty of Pharmacy, Osaka Medical and Pharmaceutical University, 4-20-1 Nasahara, Takatsuki, Osaka, 569-1094, Japan. yuko.kambayashi@ompu.ac.jp.
  • Department of Education and Research Center for Pharmacy Practice, Faculty of Pharmaceutical Sciences, Doshisha Women's College of Liberal Arts, 97-1 Kodominamihokotate, Kyotanabe, Kyoto, 610-0395, Japan.
  • School of Pharmacy, Hyogo Medical University, 1-3-6 Minatojima, Kobe, Hyogo, 650-8530, Japan.

Zitieren

APA

Kanbayashi, Y., Tsuchiya, E., Shimizu, T., & Uchida, M. (2024). Evaluation of time-to-onset and outcome of cardiac adverse events related to pembrolizumab using post-marketing surveillance in Japanese patients. DARU Journal of Pharmaceutical Sciences. https://doi.org/10.1007/s40199-024-00516-z

Vancouver

Kanbayashi Y, Tsuchiya E, Shimizu T, Uchida M. Evaluation of time-to-onset and outcome of cardiac adverse events related to pembrolizumab using post-marketing surveillance in Japanese patients. DARU Journal of Pharmaceutical Sciences. 2024. doi:10.1007/s40199-024-00516-z

BibTeX
@article{Kanbayashi2024,
  author = {Kanbayashi, Yuko and Tsuchiya, Eren and Shimizu, Tadashi and Uchida, Mayako},
  title = {Evaluation of time-to-onset and outcome of cardiac adverse events related to pembrolizumab using post-marketing surveillance in Japanese patients},
  journal = {DARU Journal of Pharmaceutical Sciences},
  year = {2024},
  doi = {10.1007/s40199-024-00516-z}
}
Kostenlos starten →